Last viewed:
ELOX
Prices are updated after-hours
ELOX
|
$0.825
-51.57%
93K
|
Health Technology
(0.0% 1d)
(-8.9% 1m)
(-88.0% 1y)
(0.0% 2d)
(2.5% 3d)
(-12.8% 7d)
(299.64%
volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 2,593,297
http://www.eloxxpharma.com
Sec
Filling
|
Patents
| 29 employees
(US) Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. It operates through the United States and Israel geographical segments. Its product includes ELX-02, a small molecule drug designed to restore production of full-length functional proteins which treats cystic fibrosis and cystinosis. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Waltham, MA.
israel
fibrosis
molecule drugs
add to watch list
Paper trade
email alert is off
Press-releases
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Published: 2024-04-16
(Crawled : 12:00)
- globenewswire.com
ELOX
|
$0.825
-51.57%
93K
|
Health Technology
| -16.33%
| O: 2.04%
H: 0.0%
C: -1.27%
elx-02
zkn-013
pharmaceuticals
program
Delisting of Securities of Latch, Inc.; Eloxx Pharmaceuticals, Inc.; Collective Audience, Inc. (f.k.a., ABRIC SPAC I); SeqLL Inc.; Nemaura Medical Inc.; LumiraDx Limited; Cemtrex Inc.; COMSovereign Holding Corp.; Global System Dynamics; Arrival; Nubia Brand International Corp.; The Alkaline Water Company Inc.; DMK Pharmaceuticals Corporation; MedAvail Holdings, Inc.; InVivo Therapeutics Holdings Corp.; and ADDvantage Technologies Group, Inc. from The Nasdaq Stock Market
Published: 2024-03-20
(Crawled : 20:00)
- globenewswire.com
COMS
|
$0.2001
37.35%
1.5K
|
Manufacturing
| 13.25%
| O: -2.27%
H: 27.46%
C: 15.87%
WTER
|
$0.0015
14185.71%
1.3K
|
Consumer Non-Durables
| 614.29%
| O: 0.0%
H: 614.29%
C: 0.0%
NDAQ
|
$61.51
0.69%
0.68%
2.8M
|
Finance
| 0.34%
| O: 0.46%
H: 3.09%
C: 1.11%
CETX
|
$2.03
-18.47%
-22.66%
140K
|
Electronic Technology
| -44.54%
| O: 0.22%
H: 1.85%
C: -2.22%
water
company
international
spac
pharmaceuticals
global
system
medical
therapeutics
market
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Published: 2024-03-13
(Crawled : 16:00)
- globenewswire.com
ELOX
|
$0.825
-51.57%
93K
|
Health Technology
| Email alert
Add to watchlist
zkn-013
rare
license
pharmaceuticals
dermatological
agreement
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Published: 2023-11-13
(Crawled : 21:00)
- globenewswire.com
ELOX
|
$0.825
-51.57%
93K
|
Health Technology
| Email alert
Add to watchlist
business
update
pharmaceuticals
financial
results
Emerging Market Trends in Muscular Dystrophy: A DelveInsight Analysis of Becker Muscular Dystrophy, Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy, and Limb-girdle Muscular Dystrophy
Published: 2023-11-06
(Crawled : 22:00)
- prnewswire.com
SRPT
|
$124.27
6.11%
5.75%
1.3M
|
Health Technology
| 46.22%
| O: 0.65%
H: 4.43%
C: 2.87%
RNA
|
News
M
|
$25.105
-0.14%
-0.14%
560K
|
Health Technology
| 374.34%
| O: -0.57%
H: 10.72%
C: 10.63%
trends
market
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
Published: 2023-10-09
(Crawled : 12:00)
- globenewswire.com
ELOX
|
$0.825
-51.57%
93K
|
Health Technology
| -81.02%
| O: -0.46%
H: 4.19%
C: 2.33%
elx-02
kidney
pharmaceuticals
study
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: 2023-09-19
(Crawled : 12:00)
- globenewswire.com
ELOX
|
$0.825
-51.57%
93K
|
Health Technology
| -84.98%
| O: -0.18%
H: 1.83%
C: 1.83%
nasdaq
direct
offering
pharmaceuticals
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Published: 2023-09-18
(Crawled : 11:00)
- globenewswire.com
ELOX
|
$0.825
-51.57%
93K
|
Health Technology
| -86.05%
| O: 1.87%
H: 0.0%
C: -8.85%
elx-02
positive
pharmaceuticals
results
study
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Published: 2023-09-07
(Crawled : 13:00)
- globenewswire.com
ELOX
|
$0.825
-51.57%
93K
|
Health Technology
| -84.41%
| O: 7.22%
H: 0.0%
C: -5.14%
elx-02
zkn-013
pharmaceuticals
program
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Published: 2023-08-14
(Crawled : 12:20)
- globenewswire.com
ELOX
|
$0.825
-51.57%
93K
|
Health Technology
| -82.74%
| O: 5.05%
H: 20.04%
C: 14.83%
business
update
pharmaceuticals
financial
results
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount